The popularity of Sildenafil initially fueled a surge for major pharmaceutical companies, however recent shifts present a complicated scenario for investors. Lower-cost versions are eroding earnings, and persistent https://honeycufy774024.idblogz.com/41527126/the-blue-pill-and-pharma-a-precarious-bet